GHP divests Urologcentrum Odenplan - positive impact on result in fourth quarter 2020

GHP Specialty Care AB ('**GHP**') has today, through subsidiary, entered into an agreement to divest its holding in the partly owned company GHP Urologcentrum Odenplan AB ('**Urologcentrum Odenplan**'). The divestment will have a positive impact on the result in the fourth quarter 2020 of about SEK 19 million (on-time item).

The consideration amounts to SEK 24,283,000 with additional interest of 4% until access date. The divestment is not conditioned to approval and will be completed in October 2020. Urologcentrum Odenplan performs diagnostics and treatment services within urology. The divested operation's net revenue amounted to SEK 26,395,000 in 2019. The buyer is Colosseum Man Holding AS. The divestment is a natural part of GHP's business, and GHP will continue to provide urology services in its operations.

"GHP continues to invest in the field of urology, partly through our other existing urology clinics in Stockholm and Skåne. Going forward our strategy is to grow, both organically and through acquisitions. In this unique case, however, we have in dialouge with our partners agreed that a sale is a good opportunity." says Daniel Öhman, CEO GHP.

Contacts

Daniel Öhman, CEO Tel: +46 (0) 708 55 37 07

Philip Delborn, CFO Tel: +46 (0) 702 12 52 64

About Us

GHP is an internationally active health care provider that operates specialist clinics in a select number of diagnostic areas through the application of a business model that is unique in the health care industry, where leading doctors and medical staff become partners and shareholders. Each clinic specialises in a particular patient group, and this leads to increased efficiency and higher quality. This is the cornerstone of GHP's business philosophy – "Quality through specialisation". GHP shares are traded on the Small Cap list of Nasdaq Stockholm under the ticker symbol "GHP".

This information is information that GHP Specialty Care is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-09-30 18:30 CEST.



Attachments

GHP divests Urologcentrum Odenplan - positive impact on result in fourth quarter 2020